Exhibit 99.1 Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update Net income of $5.9 million and$11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from$118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty Q3 2025 vs Q3 2024 Highlights Nine-Month 2025 Highlights Business Update 1 • Quarterly reven ...